uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease
Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden..
Vrije Univ Amsterdam Med Ctr, Alzheimer Ctr, Amsterdam, Netherlands.;Vrije Univ Amsterdam Med Ctr, Dept Neurol, Amsterdam, Netherlands..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Geriatrics.
Karolinska Inst, Ctr Alzheimer Res, Dept NVS, Stockholm, Sweden..
Show others and affiliations
2015 (English)In: Alzheimer's & Dementia, ISSN 1552-5260, E-ISSN 1552-5279, Vol. 11, no 10, 1180-1190 p.Article in journal (Refereed) PublishedText
Abstract [en]

Introduction: Synaptic dysfunction is an early event in Alzheimer's disease (AD) pathogenesis and directly related to cognitive impairment. Consequently, synaptic biomarkers may be valuable tools for both early diagnosis and disease stage. Neurogranin (Ng) is a postsynaptic protein involved in memory consolidation. Methods: We developed three monoclonal anti-Ng antibodies. Mass spectrometry and a novel enzyme-linked immunosorbent assay were used to analyze cerebrospinal fluid (CSF) Ng in three independent clinical cohorts including patients with AD dementia (n = 100 in total), mild cognitive impairment patients (MCI), (n = 40) and controls (n = 80 in total). Results: We show in three independent clinical cohorts a marked increase in CSF Ng levels in AD dementia (P < .001 in all studies). In addition, high CSF Ng levels at the MCI stage predicted progression to dementia due to AD with a hazard ratio of 12.8 (95% confidence interval 1.6-103.0, P = .02). In amyloid-positive MCI patients, high CSF Ng correlated with a more rapid change in cognition during clinical follow-up (P = .03). Discussion: These results suggest that CSF Ng is a novel AD biomarker that may be used to monitor synaptic degeneration, and correlates with the rate of cognitive decline in prodromal AD.

Place, publisher, year, edition, pages
2015. Vol. 11, no 10, 1180-1190 p.
Keyword [en]
Neurogranin, Alzheimer's disease, Mass spectrometry, ELISA, Mild cognitive impairment, Prognostic marker
National Category
URN: urn:nbn:se:uu:diva-268702DOI: 10.1016/j.jalz.2014.10.009ISI: 000363968000007PubMedID: 25533203OAI: oai:DiVA.org:uu-268702DiVA: diva2:880383
Swedish Research Council, 14002Swedish Research Council, K2010-63P-21562-01-4Swedish Research Council, K2011-61X-20401-05-6Knut and Alice Wallenberg FoundationStiftelsen Gamla TjänarinnorMagnus Bergvall FoundationThe Swedish Brain FoundationThe Royal Swedish Academy of Sciences

De två första författarna delar förstaförfattarskapet.

Available from: 2015-12-09 Created: 2015-12-09 Last updated: 2015-12-09Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Ingelsson, MartinLannfelt, Lars
By organisation
In the same journal
Alzheimer's & Dementia

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 179 hits
ReferencesLink to record
Permanent link

Direct link